A 5 M€ fundraising for Ad Scientiam 🚀

We are delighted to welcome TechLife Capital as a new lead investor. This milestone marks a key step for Ad Scientiam as we strengthen our portfolio of digital biomarkers, explore new therapeutic areas, and reaffirm our ambition to become the global leader in digital biomarkers.

For over 10 years, we have placed medical and technological innovation at the service of patients and healthcare professionals, and we are more determined than ever to transform real-life monitoring of severe and disabling diseases..

Check out our Press releases for all the details.

Share